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Placebo effects are positive outcomes that are not due 
to active treatment components, which may be elici-
ted even when patients are aware of receiving an inert 
substance (open-label). This proof-of-principle study 
investigated for the first time whether open-label pla-
cebo effects on itch can be induced by verbal sugges-
tions alone. Ninety-two healthy volunteers were ran-
domized to experimental (open-label suggestions) or 
control (no suggestions) groups. Self-reported itch 
evoked by histamine iontophoresis was the primary 
study outcome. In addition, itch expectations, skin 
condition and affect were assessed. The experimen-
tal group expected lower itch than the control group, 
which was, in turn, related to less experienced itch in 
this group only, although no significantly different itch 
levels were reported between groups. The results il-
lustrate a potential role for open-label placebo effects 
in itch, and suggest that further study of verbal sug-
gestions through an extensive explanation of placebo 
effects might be promising for clinical practice.
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Itch is the most common somatosensory symptom in skin conditions such as psoriasis and atopic dermati-
tis, and can cause significant impairment in patients (1). 
For example, itch has previously been associated with 
impaired quality of life, a reduction in social activities, 
reduced quality of sleep, concentration problems, and 
depression (2). Current treatments are often aimed at 
reducing the severity of the skin condition through 
pharmacological interventions with, for example, (to-
pical) antihistamines or corticosteroids. However, these 
interventions have usually shown limited effects and are 
often accompanied by side-effects (3, 4). Over recent 
years, researchers have aimed to identify other factors 
involved in the experience of itch that might be used to 
improve treatment effectiveness (5). A promising factor 
influencing the experience of itch without requiring 
medication is the placebo effect (6–8). 
Placebo effects are beneficial effects of pharmaco-
logically inert treatment components (6, 8). A recent 
meta-analysis indicated that itch may be especially prone 
to such effects, and that up to 30% of improvement in 
itch may be attributed to the occurrence of placebo 
effects rather than pharmacological intervention (9). 
Experimental studies further demonstrate that placebo 
effects can be induced in itch by providing suggestions 
that a treatment is able to alleviate itch, or by suggesting 
that a test that generally provokes itch will elicit no itch 
(10, 11). In addition, there is evidence that the opposite 
instructions (e.g. suggesting that a treatment will sensi-
tize a person to itch) can increase itch, a phenomenon 
known as the nocebo effect (10, 12–14). In addition to 
studies investigating the effects of verbal suggestions 
on self-report measures such as itch, a few studies have 
investigated whether verbal suggestions can influence 
physical skin conditions, for example wheal and flare 
size in response to histamine (11, 12, 14, 15). It has 
been demonstrated recently that negative outcome ex-
pectations, or nocebo, can result in a greater physical 
skin response, as demonstrated by larger flare size in 
response to histamine and wheal size in response to 
natrium chloride following negative verbal suggestions 
(14). Placebo (and nocebo) effects can be established 
by a patient’s belief in treatment effectiveness and out-
comes (6, 8, 16–18). The main working mechanisms of 
placebo effects include associative learning processes, 
such as conditioning, and expectations, such as positive 
information regarding treatment outcomes provided by 
means of verbal suggestions (6, 8, 16, 18).
Most studies on placebo effects have used an experi-
mental approach eliciting placebo effects by providing 
uncertainty or deception about the specific treatment pro-
vided (e.g. actual medicine or placebo). It is assumed that 
the benefits that patients experience from inert substances 
stem from the covert belief that a pharmacologically ef-
fective treatment is being given (19). This uncertainty or 
deceptive component complicates the potential utiliza-
tion of placebo effects in clinical practice, considering 
that omission of treatment information and provision 
of deceptive information are unethical (18, 20). Studies 
have, however, indicated that a placebo treatment can 
still be effective when patients are aware of receiving an 
inert treatment (21–28). Most of these studies on open-
label placebo treatment have reported medium-to-large 
effect sizes (21, 22, 25), comparable to the effect sizes 
found by studies in which patients were not informed 
about receiving an inert substance (closed-label placebo; 
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(29)). A recent pilot study furthermore demonstrated 
that such an open-label placebo treatment may also be 
effective for symptoms of allergic rhinitis, including itch 
(28). Within this pilot study, symptom improvement by 
open-label placebo treatment was furthermore associated 
with higher subjective well-being (28).
It is not yet clear by which mechanisms open-label 
placebo effects may be elicited. Previous open-label 
studies have combined different components, namely the 
administration of an inert pill and a rationale concerning 
placebo effectiveness and its mechanisms (21–28). This 
complicates the understanding of which of these compo-
nents contribute to open-label placebo effects, or the ex-
tent to which they contribute. It is not yet known whether 
providing a positive rationale (e.g. verbal suggestions) 
exclusively might be sufficient to induce open-label 
placebo effects by changing expectations regarding itch 
and affecting the response to an itch stimulus. If proven 
possible, this would facilitate clinical applications; for 
example, by optimizing existing treatment methods for 
chronic itch by improving doctor–patient communication.
The aim of the current proof-of-principle study was 
to investigate for the first time in an open-label design 
whether positive verbal suggestions about itch in re-
sponse to an itch-provoking test without combining it 
with an inert treatment can induce positive outcome 
expectancies and reduce self-reported itch in response to 
a short-term itch-provoking histamine test. Physical and 
self-reported skin condition and positive and negative 
affect were secondary outcomes. In addition, the specific 
role of expectations in the effects of open-label verbal 
suggestions on itch was examined. It was expected that 
open-label positive verbal suggestions about itch would 
reduce the level of itch that participants expected to ex-
perience during the histamine test as well as the mean 
level of itch experienced during the test, compared with 
a control condition that received no verbal suggestions. 
In addition, it was expected that open-label positive ver-
bal suggestions compared with the control group would 
reduce the severity of the participants’ skin condition, 
and that verbal suggestions would diminish changes in 
positive and negative affect as a consequence of itch 
induction by histamine iontophoresis. 
METHODS
The study was approved by the Medical Ethical Committee at 
the Leiden University Medical Center, The Netherlands (protocol 
number NL54570.058.15) and performed in accordance with 
the Declaration of Helsinki. All participants provided written 
informed consent. 
Participants
Healthy male and female volunteers were recruited primarily 
through advertisements and flyers at various sites of Leiden Uni-
versity, The Netherlands, and through online media. Participants 
were included if they were between 18 and 35 years old and had a 
sufficient understanding of written and spoken Dutch. Exclusion 
criteria consisted of severe somatic or psychological morbidity (e.g. 
heart and lung diseases, histamine intolerance, or the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR) psychiatric diagnoses) that might interfere 
with the study protocol, current chronic itch or pain complaints, 
current medication use (analgesics, anti-inflammatory drugs, 
antihistamines, or antibiotics), or pregnancy. In order to prevent 
potential influences on the response to the itch stimulus, participants 
were asked to refrain from the consumption of food, caffeine, and 
smoking 2 h prior to the laboratory session. In addition, they were 
asked to avoid heavy exercise 12 h, and alcohol and drugs 24 h prior 
to the session. This was verified at the beginning of the laboratory 
session, including a brief check of participant eligibility.
Study design
A between-subjects experimental randomized controlled trial 
design was used. Subjects considered eligible to participate in the 
study were invited to a 1-h laboratory session and randomized to 
either the experimental (i.e. open-label positive verbal suggestions) 
group or the control (no verbal suggestions) group. The randomi-
zation sequence was acquired through the use of an online ran-
dom number generator (www.random.org, Dublin, Ireland). The 
laboratory session was conducted by 2 experimenters; only one 
of whom was aware of group allocation and provided the verbal 
suggestions. Participants and the experimenter who conducted the 
outcome assessments were unaware of group allocation during 
the laboratory session.
Materials and measures
Histamine iontophoresis. Histamine was applied to the skin through 
transdermal iontophoresis (Chattanooga Group, Hixson, TN, 
USA). This method has been used previously to experimentally 
induce itch in healthy volunteers (10, 30, 31). A 0.3% diphosphate 
histamine solution was prepared in distilled water with propylene 
glycol and hypromellose 4000 mPa. An electrode (Iogel, Iomed, 
DJO Global, Hannover, Germany) was prepared that contained 
2.5 ml of the histamine solution. The electrode had an active area 
of 11.7 cm2 and was placed on the volar side of the non-dominant 
forearm, and the reference electrode was placed on the volar sur-
face of the upper arm. Current level was set at 0.4 mA. Histamine 
iontophoresis was applied for 2.5 min, after which the electrodes 
were removed and a follow-up period of 4 min was started. 
Verbal suggestions. Participants were informed prior to the ses-
sion that the study aimed to investigate individual differences 
in the experience of itch. Upon arrival at the laboratory session, 
the following general instructions were given to all participants: 
“During the test, histamine will be applied on your skin by means 
of a small electrical current. This elicits a response that is similar 
to a mosquito bite. Your skin may become red and may swell up.” 
In the experimental group exclusively, participants were given 
the following verbal suggestion, followed by an open-label instruc-
tion: “Previous research indicates that the test elicits little or no itch 
in most healthy people, meaning in 95% of cases. We would also 
like to give you some extra information. From research we know 
that expectations play a large role in how itch is experienced, for 
example through giving information about what to expect from 
a test such as this one. I just told you that the test that you are 
about to do elicits little or no itch in most healthy people. From 
research we know that this suggestion will really cause people to 
experience little itch, even when they are aware of receiving this 
suggestion. Thus, the suggestion alone that the test causes little or 
no itch will already cause you to experience little itch.” 
Process measure: expectations about itch. Participants were as-
ked to indicate on the computer the level of itch they expected to 
experience, using a numerical rating scale (NRS) ranging from 0 
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(“no itch at all”) to 10 (“worst itch ever experienced”). Expected 
itch was assessed at 2 time-points during the laboratory session: 
once during baseline assessments and once after the verbal sug-
gestions but before the histamine iontophoresis.
Primary outcome measure: self-reported itch. The level of expe-
rienced itch during histamine iontophoresis was assessed verbally 
every 30 s during iontophoresis and during a 4-min follow-up 
period, using the same NRS as described in the previous paragraph. 
Directly following histamine iontophoresis, the mean experienced 
itch during iontophoresis was assessed verbally using the same 
NRS. As part of a series of online questionnaires that assessed 
baseline measures (see Procedure), the level of itch experienced 
prior to iontophoresis was measured graphically by dragging a 
slider over a bar slide using the same NRS, with a 2-decimal score 
depicted next to the bar slide. 
Secondary outcome measure: physical skin condition. Wheal 
size and flare size in response to histamine iontophoresis were 
traced on a 1 cm2 gridded, transparent sheet following histamine 
application using a 0.4-mm black permanent marker (Staedtler, 
Germany). Scans of the sheets were then uploaded and analysed 
using ImageJ (32). Images were calibrated to the 1 cm2 grid in 
ImageJ, after which wheal and flare area were estimated in cm2 
through tracking the outer edges of the drawn wheal and flare areas. 
In addition, skin temperature was assessed following histamine 
iontophoresis on the application site on the arm using a hand-held 
infrared digital thermometer (accuracy ±2.0°C, resolution 0.1°C, 
BaseTech, Conrad Electronic Benelux B.V., Hirschau, Germany). 
The thermometer was held vertically approximately 1 cm above 
the area. To control for individual differences in skin temperature, 
a second measurement was taken of a similar skin area of the 
contralateral arm and used as a covariate in the analysis. 
Secondary outcome measure: self-reported skin condition. The 
Sensitive Scale-10 (SS-10) was used to assess self-reported skin 
condition (33). This scale assesses the severity of skin sensitivity 
over the past 3 days through evaluation of 9 skin condition items 
(e.g. burning, tautness, itch, and redness of the skin) on a 0 (“zero 
intensity”) to 10 (“intolerable intensity”) scale. In addition, the 
scale assesses skin irritation on a visual analogue scale (VAS), 
ranging from 0 to 10 (33). The SS-10 total score was calculated 
by summing all items, with a higher score indicating more intense 
skin sensations (range 0–100). Upon arrival in the laboratory, 
participants completed the SS-10 for a baseline measurement. 
A slightly adjusted version of the SS-10 was used to assess self-
reported skin condition following histamine iontophoresis, with 
participants having to indicate the symptoms experienced during 
histamine iontophoresis rather than symptoms experienced during 
the past 3 days. In the current study, Cronbach’s alpha was 0.83 for 
baseline SS-10 and 0.89 for the adjusted post-test SS-10. 
Secondary outcome measure: positive and negative affect. The 
Positive and Negative Affect Schedule (PANAS) was used to as-
sess positive (PA) and negative affect (NA; (34)). In this 20-item 
questionnaire, participants indicated the extent to which they ex-
perience specific emotions (e.g. interested, excited, or nervous) at 
that moment on a 1 (“very slightly or not at all”) to 5 (“extremely”) 
scale. PA total score was calculated by summing the 10 positive 
items of the scale and NA total score by summing the 10 negative 
items (total score range 10–50, with higher scores indicating higher 
PA or NA). Baseline affect was measured upon arrival in the labo-
ratory (baseline PA and NA) and following histamine iontophoresis 
(post-test PA and NA). Cronbach’s alpha was 0.83 for baseline PA 
and 0.79 for post-test PA. For NA, Cronbach’s alpha was 0.82 and 
0.91, respectively. To examine group differences in the changes 
over time in positive and negative affect in response to the hista-
mine iontophoresis, PA and NA change scores were calculated for 
each scale by subtracting baseline scores from post-test scores. For 
both positive and negative affect change scores, positive scores 
indicated an increase in that particular affect. 
Procedure
Prior to being invited to a laboratory session, participants were 
provided with written information about the study. Participants 
subsequently completed a series of online questionnaires asses-
sing the screening criteria and several personality characteristics, 
which are not described here since they are unrelated to the aim 
of the current study. Prior to this, participants provided written 
informed consent for the online questionnaires. At the start of 
the laboratory session, the study procedures were explained to 
all participants and written informed consent for the entire study 
was provided, following which participants were given instruc-
tions regarding the histamine test by the first experimenter. Next, 
baseline measurements were taken of itch, self-reported skin 
condition, positive and negative affect, and itch expectations be-
fore verbal suggestions. Positive expectations were then induced 
through open-label verbal suggestions in the experimental group. 
Participants then again indicated the level of itch they expected 
to experience. In the meantime, the first experimenter left the 
room and was replaced with the second experimenter. Histamine 
iontophoresis was then conducted by this second experimenter. 
During histamine iontophoresis as well as during the 4-min follow-
up period, the level of itch participants experienced was assessed 
verbally on the NRS every 30 s. Directly following iontophoresis, 
mean experienced itch during iontophoresis was assessed, again 
using the same NRS. Subsequently, measurements of physical skin 
condition (e.g. wheal, flare) were taken and post-test questionnaires 
SS-10 and PANAS were administered. The second experimenter 
was then replaced by the first experimenter and participants were 
debriefed about group allocation and the true purpose of the study. 
Statistical analyses
A power calculation for an analysis of covariance (ANCOVA) 
using G*Power 3.1 (35) indicated that a total of 92 participants 
was needed to achieve a power of β=0.80 at a 2-sided significance 
level of α=0.05 to detect a Cohen’s d effect size of at least 0.30 on 
the primary outcome measure of mean itch. Analyses were perfor-
med using SPSS 21.0 for Windows (IBM SPSS Inc., Chicago, IL, 
USA). Variables were checked for normal distribution. In order 
to achieve normal distributions, square root transformations were 
applied for baseline itch and self-reported skin condition, as well 
as the physical skin condition parameters wheal size and flare 
response, and a log10 transformation was applied to baseline skin 
temperature. For PANAS negative affect change scores, trans-
formations failed to achieve a normal distribution; therefore, a 
non-parametric Kruskal–Wallis test was used to examine group dif-
ferences on this outcome measure. χ2 tests and general linear model 
(GLM) ANOVAs were used to detect differences between groups 
on demographic factors and baseline measurements of itch, self-
reported skin condition (SS-10), and positive and negative affect. 
The primary outcome measure of mean experienced itch, as rated 
by participants following histamine iontophoresis (mean ± standard 
deviation (SD) 3.3 ± 1.6) was correlated very highly with the mean 
score of itch ratings during the histamine iontophoresis (mean ± SD 
2.9 ± 1.4; r = 0.93, p < 0.001), supporting the reliability of the itch 
measure used. To examine whether the groups differed on the 
process measure of itch expectation (post-verbal suggestions) 
and on the primary outcome of mean itch experienced during the 
histamine test, 2 GLM ANCOVAs were conducted, with baseline 
expectations and baseline itch level included as covariates in the 
analyses, respectively. Similar ANCOVAs were conducted for the 
secondary outcome measures of the SS-10 and skin temperature. 
For wheal and flare size in response to histamine iontophoresis, 
as well as for PANAS positive affect change scores, GLM ANO-
VAs were performed. As an effect size measure, Cohen’s d was 
calculated for analyses on the primary and secondary outcome 
parameters, with d = 0.2, 0.5 and 0.8 being interpreted as a small, 
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medium and large effects, respectively (36). In order to explore 
whether itch expectation after the verbal suggestions was related to 
the level of mean experienced itch during histamine iontophoresis, 
and whether this relationship differed between groups, separate 
effects, as well as an interaction effect of post-verbal suggestions 
itch expectation and group, were examined in a multiple regres-
sion analysis, with baseline itch and pre-verbal suggestions itch 
expectation as covariates. Post-verbal suggestions itch expectation 
was centred prior to the analysis. All analyses were conducted 
2-sided with a significance level of α < 0.05. 
RESULTS
Group characteristics
A total of 139 potential participants expressed interest in 
the study, of whom 24 were excluded due to medical mor-
bidity (e.g. migraine, asthma, presence of a skin disorder) 
and 9 due to psychological morbidity (e.g. depression, 
anxiety). In addition, 14 persons refrained from participa-
tion for other reasons (e.g. no response after first postal 
contact). In total, the sample consisted of 92 healthy male 
(n = 17) and female (n = 75) participants between 18 and 
26 years of age (mean ± SD 21.3 ± 1.9 years). Participants 
were of Dutch (98%), Dutch–Turkish (1%), or German 
(1%) nationality. Of all participants, 41% had a partner, 
of whom 7% were living with a partner or were married. 
Of the female participants, 69% used oral contraceptives. 
Randomization resulted in a total of 46 participants in 
the experimental group and 46 participants in the control 
group. Data for one participant in the experimental group 
were excluded from analysis, due to technical issues during 
histamine iontophoresis. χ2 tests and ANCOVAs revealed 
no differences between groups with regard to age, sex, edu-
cation, or nationality (all p-values ≥ 0.19). Table I displays 
the means ± SD for the baseline measurements, and the 
primary and secondary study outcomes for the 2 groups. 
Effects of verbal suggestions on the process measure of 
post-suggestion expected itch
As shown in Fig. 1, in the experimental group significant-
ly lower itch expectations were reported following verbal 
suggestions (mean ± SD 2.66 ± 2.04) than in the control 
group (mean ± SD 5.73 ± 1.51). A statistically significant 
large-sized effect of verbal suggestions on post-verbal 
suggestions itch expectation, controlled for pre-verbal 
suggestions itch expectation, was demonstrated in the 
ANCOVA; F(1, 89)=59.57, p < 0.001, Cohen’s d = 1.62. 
Effects of open-label verbal suggestions on the mean 
level of itch during histamine iontophoresis 
No statistically significant difference between groups 
in mean self-reported itch in response to histamine 
iontophoresis, controlled for baseline itch, was found in 
the ANCOVA; F(1, 90)=1.40, p = 0.24, Cohen’s d = 0.21. 
Multiple regression analysis to test for interaction ef-
fects between post-verbal suggestions itch expectation 
and group on self-reported mean itch during histamine 
iontophoresis did not show significant main effects for 
group (β = 0.06, p = 0.69) or post-verbal suggestions 
expected itch (β = 0.36, p = 0.10). As expected, baseline 
itch and pre-verbal suggestions expected itch were not 
Table I. Means ± standard deviations for baseline and outcome 
measures of study parameters per group
Experimental 
group
(n = 45)
Control 
group
(n = 46) p-value 
Process measure
Pre-VS itch expectationa 4.84 ± 1.61 5.19 ± 1.83 0.28
Post-VS itch expectationa 2.66 ± 2.04 5.73 ± 1.72 < 0.001
Primary outcome measure
Baseline itch 0.47 ± 0.84 0.39 ± 0.89 0.27
Self-reported mean itch 3.14 ± 1.61 3.46 ± 1.51 0.24
Secondary outcome measures
Subjective skin response
Baseline self-reported skin condition 6.94 ± 9.12 5.02 ± 5.50 0.16
Self-reported skin conditionb 25.88 ± 13.55 29.88 ± 14.48 0.059
Physical skin response
Wheal size (cm2) 10.40 ± 2.67 11.23 ± 2.67 0.16
Flare response (cm2) 33.81 ± 7.85 35.54 ± 10.19 0.44
Skin temperature (°C) 33.35 ± 1.21 33.54 ± 1.38 0.26
Change in positive and negative affect
Baseline positive affect 24.74 ± 6.34 25.54 ± 6.21 0.54
Post-histamine positive affect 24.09 ± 6.58 22.61 ± 4.69 0.22
Baseline negative affectd 12.00 ± 4.00 12.00 ± 4.00 0.67
Post-histamine negative affectd 11.00 ± 3.00 11.00 ± 2.00 0.53
Change in positive affectc –0.64 ± 3.22 –2.93 ± 3.69 0.002
Change in negative affectc,d 0.00 ± 2.00 0.00 ± 3.00 0.98 
aVS: open-label verbal suggestions. bAs measured by an adjusted version of the 
Sensitive Scale-10 (33). cChange in mood parameters measured by the Positive 
and Negative Affect scales (34) over time, as calculated by subtracting the baseline 
scores from the post-histamine scores. More positive scores indicate an increase 
over time, whereas zero indicates no change and more negative scores indicate 
a decrease over time. dMedian ± interquartile range is presented, with p-value 
calculated by a non-parametric Kruskal–Wallis test.
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Fig. 1. Mean numerical rating scale 
scores for the experimental (open-
label positive verbal suggestions; 
n = 45) and control (no suggestions; 
n = 46) group for the process measure 
and primary study outcome measure. 
(A) Expected itch on the histamine 
iontophoresis test before and after 
instructions. (B) Mean itch in response 
to histamine iontophoresis. Error bars 
represent standard error of the mean. 
***p < 0.001.
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predictive of self-reported mean itch during histamine 
iontophoresis (p ≥ 0.36). However, a statistically signifi-
cant interaction effect for group × post-verbal suggestions 
itch expectation was found (p = 0.04), indicating that in 
the experimental group only, lower expected itch was 
associated with lower self-reported mean itch during the 
histamine iontophoresis, whereas no association between 
expected and experienced itch was found in the control 
group (full model: R2=0.11, F(5,89)=2.04, p = 0.08; see 
also Fig. 2). 
Effects of open-label verbal suggestions on skin condition 
Self-reported skin condition (SS10) scores following 
histamine iontophoresis were marginally significantly 
lower, indicating better self-reported skin condition, in 
the experimental group (25.88 ± 13.55) than in the control 
group (29.88 ± 14.48; F(1, 90)=3.67, p = 0.059, Cohen’s 
d = 0.29). No statistically significant group differences 
were found for the physical parameters wheal and flare 
size, and skin temperature in response to histamine 
iontophoresis (p ≥ 0.14). 
Effects of open-label verbal suggestions on change in 
positive and negative affect 
A statistically significant and medium-sized effect of 
verbal suggestions on PA change scores was demon-
strated compared with the control group; F(1, 90)=9.93, 
p = 0.002, Cohen’s d = 0.66. Participants in the control 
group showed a stronger decline in positive affect from 
before to after the histamine iontophoresis (mean ± SD 
PA change score –2.93 ± 3.69, range –15 to 5), whereas 
participants in the experimental group remained more 
stable over time (mean ± SD PA change score –0.64 ± 3.22, 
range –8 to 8). The Kruskal–Wallis test revealed no 
statistically significant difference in NA change scores 
between the experimental and control groups (p = 0.98). 
DISCUSSION
This proof-of principle study investigated for the first time 
whether open-label positive verbal suggestions alone can 
induce outcome expectations and reduce the level of itch 
experienced during histamine iontophoresis. It was de-
monstrated that the open-label positive verbal suggestions 
were successful in reducing the level of itch participants 
expected to experience during histamine iontophoresis, 
but not in reducing itch experienced in response to the 
histamine test. The relevance of expectations was demon-
strated further by showing that a decrease in expected 
itch in response to verbal suggestions was significantly 
associated with lower experienced itch in response to 
the histamine test in the experimental group, but not in 
the control group. Moreover, a tendency was found for 
patients to rate the severity of the self-reported skin condi-
tion as lower following open-label suggestions, compared 
with the control group, but no effects on physical skin 
condition were found. Furthermore, a significantly smal-
ler decrease in positive, but not negative, affect was found 
in response to the histamine test in the verbal suggestions 
group, compared with the control group. 
These findings, that open-label positive verbal sugges-
tions did not affect actual experienced level of itch, are not 
in line with the findings of previous studies on open-label 
placebo in, for example, allergic rhinitis, low-back pain 
and irritable bowel syndrome (21–26, 28). This may be due 
to the current study using verbal suggestions exclusively 
without an inert treatment. In previous studies, open-label 
placebo effects have been induced by asking participants 
to ingest pharmacologically inert pills combined with 
providing a suggestive positive rationale to participants, 
in which it was explained how placebo effects induce 
symptom improvement and in which the effectiveness 
of placebo treatment was emphasized (21, 22, 28). It is 
possible that the mere act of taking medicine could have 
elicited stronger placebo effects. Influential conditioning 
theories of placebo effects state that the placebo effect is a 
conditioned response that is a result of previously learned 
associations (16). As pointed out previously by Carvalho et 
al. (21), the rituals surrounding administration of medica-
tion may have activated previously learned associations 
between symptom alleviation and capsule or pill inges-
tion. Considering that all previous open-label studies have 
been conducted in patient populations in which medica-
tion administration is common, it seems likely that these 
effects were further strengthened by associative learning 
pathways and heightened relevance of symptom impro-
vement for patients in these studies. The current study, on 
the contrary, sought to examine the ability to elicit placebo 
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effects by provision of positive verbal suggestions without 
coupling with an inert substance in healthy participants. 
Investigating these effects not only provides information 
regarding the mechanisms of open-label placebo, but if 
proven possible would also allow for easier implementa-
tion in clinical practice, for example by optimizing the 
information provided to patients in existing treatment in 
order to maximize placebo effects. The placebo effects 
induced in the current study may have had some impact, as 
evidenced by the successful expectation induction, which 
was in turn related to lower itch level, but speculatively 
may not have been strong enough to significantly alter the 
way in which itch was actually perceived in response to 
the itch stimulus. 
Next to effects on itch expectancy, there was also a 
tendency for participants in the experimental group to 
indicate better self-reported skin condition following 
the histamine test than controls. That positive affect in 
the open-label suggestions group also decreased signi-
ficantly less than in the control group upon itch induc-
tion also indicates that some effects may have occurred. 
This may be compared with the previous finding that 
improvement in allergic rhinitis by open-label placebo 
treatment is related to higher wellbeing (28). However, 
no effects of open-label positive verbal suggestions on 
physical skin condition (i.e. wheal and flare size, skin 
temperature) were found, which is in line with previous 
findings for closed-label placebo effects on physical skin 
responses (11, 15), but not with findings for closed-label 
nocebo effects on physical skin response (14). Although 
indications were found that the verbal suggestions may 
have mostly influenced subjective measures, they were 
potentially not strong enough to significantly alter the 
symptom and physical outcomes between groups.
In this study, a potential predictive role of a change in 
itch expectations due to open-label verbal suggestions 
was observed for the resultant itch level that was reported 
in response to the histamine test, showing that a larger 
decrease in itch expectations was associated with lower 
experienced itch. This is in accordance with the idea 
that placebo effects can impact symptoms by means 
of changing people’s expectations and is in line with 
the provided rationale explaining that expectations can 
alter the way in which itch can be perceived. Whereas 
in closed-label placebo studies the expectation that a 
certain treatment or medicine results in symptom im-
provement is attributed to the provision of uncertainty 
or deceptive information by the doctor or experimenter 
(27, 37), in open-label studies this might be attributed to 
the provision of a rationale on how placebo effects could 
instead lead to beneficial treatment outcomes. For both, 
the actual expectation of symptom improvement of the 
patient is suggested to be present and to have an impact. 
Previous studies, however, have always combined open-
label placebo pill administration with the rationale that 
explained that “the placebo effect can be powerful” and 
that “the body may respond automatically to placebo 
treatment” (21, 22, 28). Furthermore, as in most of these 
trials, open-label placebo treatment was given along 
with treatment as usual (21, 22, 28) and the effects that 
patients might experience were not specified, placebo 
effects may have been enlarged by simultaneously occur-
ring pharmacologically-induced reduction in symptoms. 
As such, it is difficult to determine the exact underlying 
cause of placebo effects in these studies. Demonstrating 
that placebo effects could be exclusively due to a posi-
tive rationale, on the other hand, would facilitate easier 
implementation in clinical practice, as no additional 
inert pills would need to be given. Instead, a positive 
framework for patients in which placebo mechanisms 
are illustrated could then potentially suffice to strengthen 
existing treatment methods for itch. 
Some strengths and limitations of this study need to be 
taken into account. This is the first study to examine the 
ability of positive verbal suggestions to induce placebo 
effects in itch in an experimental, open-label design wit-
hout combining it with an inert treatment. The relatively 
large sample size and use of a homogenous participant 
group allowed for a robust indication of effect sizes. 
Assessment of outcome variables was conducted by an 
experimenter who was blinded to group allocation in 
order to minimalize reporting bias. However, as in all 
research in which placebo effects are induced by verbal 
suggestions, reporting bias cannot be ruled out, as partici-
pants may still have adjusted their answers due to the ex-
plicit instructions on expectations. Fourthly, participants 
underwent histamine iontophoresis only once and most 
were unfamiliar with histamine iontophoresis. Prior to the 
test, participants were told that the response to histamine 
iontophoresis could feel like a mosquito bite. However, 
since the participants did not know exactly what to expect 
during the test, this lack of a reference frame for itch 
may have complicated changing these expectations and, 
consequently, the induction of placebo effects. Future 
studies could examine whether providing a more familiar 
stimulus, for example by providing a baseline test prior 
to placebo induction, would lead to clearer expectation 
effects (13). Finally, while in the open-label verbal sug-
gestions a distinction was made between the suggestion 
(i.e. “research indicates that the tests elicits little to no 
itch in most healthy people, meaning in 95% of cases”) 
and the open-label rationale, both were given to one 
group only. As such, we cannot distinguish between ef-
fects of the suggestion itself and the open-label rationale 
that followed. For future research, it may also be useful 
to compare open-label with closed-label placebo induc-
tion, in order to better distinguish between open- and 
closed-label placebo effects in itch.
In conclusion, this proof-of-principle study indicates 
for the first time that open-label positive verbal sugges-
tions were able to reduce itch expectations prior to a his-
tamine test. Also, open-label suggestions were associated 
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with a smaller impact on positive affect and indications 
were found for a more positive self-perceived, but not 
physical, skin condition in response to the validated 
histamine test. However, the suggestions did not signifi-
cantly impact actual itch levels between groups, although 
within the experimental group an association was found 
between expected and experienced itch after verbal sug-
gestions. Future research should aim to strengthen the 
open-label verbal suggestions, for example by providing 
a more explicit explanation of placebo mechanisms and 
effectiveness, in order to investigate whether open-label 
placebo effects can be induced in itch without the need 
to administer a substance. 
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